If you have been reading about c-Met receptor and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2026-06-24. Numbers and descriptions here follow the published literature rather than marketing material.
Dihexa is not approved as a medicine in major regulatory jurisdictions. It is commonly sold as a research chemical for laboratory use, though such products may not be standardized or independently verified. Scientific literature on dihexa includes in vitro assays, rodent studies, and reviews that discuss its proposed mechanism. The distinction between peer-reviewed findings and commercial promotion is important when evaluating available information. Open questions include its precise binding interactions, pharmacokinetics, and whether animal results translate to human biology.
Dihexa is a synthetic peptide derived from angiotensin IV, a naturally occurring fragment of the renin-angiotensin system. Researchers modified the angiotensin IV structure to improve metabolic stability and central nervous system activity. It is frequently described as a hepatocyte growth factor mimetic because it can activate the c-Met receptor pathway in experimental systems. Its development reflects interest in small peptides that influence synaptic plasticity and cognitive processes. Most information comes from preclinical studies rather than controlled human trials.
Laboratory characterization of dihexa typically relies on reverse-phase high-performance liquid chromatography for purity and mass spectrometry for identity. These methods are standard for synthetic peptides and help distinguish the target compound from related impurities or degradation products. Because dihexa is a small peptide-like molecule, it may be susceptible to hydrolysis under certain conditions. Storage recommendations generally emphasize low temperature, dryness, and protection from light. Analytical certificates from suppliers vary in detail, so independent verification can be important for research use.
Reported effects of dihexa are often described in terms of synaptogenesis, a process by which neurons form new synaptic connections. This concept is biologically plausible but difficult to measure directly in living humans. Animal behavioral tests can suggest memory or learning changes, yet such tests have limitations and may not translate to people. The literature includes conflicting or incomplete findings, and some studies are small. As a result, the mechanism remains a subject of investigation rather than a settled explanation.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide | Derived from angiotensin IV and modified for stability. |
| Proposed mechanism | c-Met/HGF pathway activation | Described as an HGF mimetic in experimental systems. |
| Common synonyms | Dihexa; N-hexanoic-Tyr-Ile-(6)-aminohexanoic amide | Name usage varies by supplier and publication. |
| Regulatory status | Not approved as a drug | Sold as a research chemical in some markets. |
| Human trial data | Limited or absent | Most evidence comes from preclinical studies. |
In laboratory settings, dihexa is typically handled as a research chemical rather than a pharmaceutical product. Suppliers may provide it as a lyophilized powder or in solution, and purity is often stated as a percentage determined by chromatographic analysis. Because independent verification is uncommon, researchers generally rely on certificates of analysis, which may include high-performance liquid chromatography and mass spectrometry data. The absence of pharmacopeial monographs means that identity, purity, and impurity profiles can vary between batches and suppliers.
Storage recommendations for peptides and peptide-like compounds usually emphasize low temperatures, desiccation, and protection from light. A common practice is to keep dry powder at -20 °C or below and to prepare solutions shortly before use. Repeated freeze-thaw cycles may degrade the material, so aliquoting is often advised. Solubility depends on the solvent; aqueous solubility may be limited, and organic solvents such as dimethyl sulfoxide are sometimes used for stock solutions. Stability data specific to dihexa are sparse, so general peptide handling guidelines are often applied instead.
Research interest in dihexa centers on its ability to promote synapse formation in cultured neurons and in some rodent experiments. These findings have been interpreted as a possible mechanism for learning and memory effects, but the evidence remains preliminary. Independent replication is limited, and study designs vary widely in species, duration, and outcome measures. Human data are scarce, so claims about cognitive enhancement in people are not supported by robust clinical evidence. The gap between laboratory signals and proven clinical benefit is substantial.
Dihexa appears in scientific literature, patent documents, and commercial catalogs under several names, which can complicate searching and verification. The compound is frequently grouped with nootropics or research chemicals, terms that describe context of use rather than regulatory approval. Such labeling may imply benefits that have not been confirmed in controlled human studies. Readers encountering promotional descriptions should distinguish between preclinical observations and established medical facts. The absence of regulatory approval is a central feature of its current status.
Dihexa is a synthetic peptide-like compound studied in preclinical research for its reported effects on synaptic growth and cognitive measures in animal models. It is often described as an analog of angiotensin IV, a naturally occurring peptide fragment. The compound has not been approved as a medicine in any major jurisdiction. Most public information comes from laboratory studies, patents, and online vendor listings rather than from large clinical trials. Its scientific status therefore differs from that of an established pharmaceutical.
In animal research, dihexa has been administered through several routes, and reports describe improved performance on spatial learning and memory tasks in rodents. These results are frequently cited in discussions of nootropic compounds. However, species differences, small sample sizes, and varied testing protocols limit how far the findings can be generalized. No large randomized controlled trials in humans have established efficacy or long-term safety. Claims about human cognitive enhancement therefore remain speculative, and the compound is best described as an experimental laboratory substance rather than a proven therapeutic or supplement.
Dihexa is a synthetic compound studied in laboratory and animal models for effects on synaptic connectivity and cognitive performance. It is often described as a peptide analog because its structure incorporates amino acid residues linked to a hexanoic acid group. The molecule is not a naturally occurring human hormone or neurotransmitter. Its name appears in research literature and online discussions, but it has not been approved as a medicine by major regulatory agencies. Most information comes from preclinical experiments rather than controlled human trials.
The compound originated from work on angiotensin IV, a peptide fragment of the renin-angiotensin system. Researchers modified angiotensin IV-related structures to produce molecules with altered stability and activity. Dihexa emerged from that effort and was reported to promote dendritic spine growth in cultured neurons. Some studies link its effects to hepatocyte growth factor signaling and the c-Met receptor, while other work points to insulin-regulated aminopeptidase. The precise primary target remains a subject of investigation, and findings may depend on cell type, assay conditions, and species.
Human data for dihexa remain absent from peer-reviewed clinical literature. As a result, questions about absorption, distribution, metabolism, excretion, and long-term safety are unresolved. Discussions often appear in nootropic forums, where anecdotal reports cannot substitute for controlled trials. Researchers have called for more rigorous pharmacokinetic and toxicological studies before any clinical evaluation. Until such data exist, dihexa is best described as an investigational research compound rather than a proven intervention.
The proposed mechanism for dihexa centers on hepatocyte growth factor, or HGF, and its receptor c-Met. HGF signaling is involved in cell growth, survival, and synapse formation. Dihexa has been described as an HGF mimetic or modulator in preclinical literature. Whether it binds c-Met directly, increases HGF availability, or acts through another route remains uncertain. This mechanistic uncertainty is a recurring theme in reviews of the compound, and no single molecular model has been confirmed across independent laboratories.
== Simple flow models == Design equations are equations relating the space time to the fractional conversion and other properties of the reactor. Different design equations have been derived for different types of the reactor and depending on the reactor the equation more or less resemble that describing the average residence time. Often design equations are used to minimize the reactor volume or volumetric flow rate required to operate a reactor.
Maurice Peston, Baron Peston (19 March 1931 – 23 April 2016) economist and Labour life peer; author of numerous scholarly academic texts and monographs on economics; research interests included macroeconomic policy and the economics of education; father of Robert Peston. Adam Phillips (psychologist)(born 19 September 1954) is a British psychoanalytic psychotherapist, essayist and author of well over twenty books, scholarly articles and academic papers; since 2003 he has been the general editor of the new Penguin Modern Classics translations of Sigmund Freud and is a regular contributor to the London Review of Books. Alexander Piatigorsky, writer, philosopher, culture theorist; winner of the 2002 Russian Bely Prize for literature Irma Brenman Pick (13 April 1934 – 3 August 2023) South African Latvian Jewish British psychologist and psychoanalyst known for her work on countertransference. She served as the president of the British Psychoanalytical Society from 1997 to 2000. Daniel Pick (born 1960); historian, psychoanalyst, university teacher, writer, broadcaster; was recipient of a senior Investigator grant from the Wellcome Trust and led research group at Birkbeck exploring history of the human sciences and 'psy' professions during the Cold War; project entitled 'Hidden Persuaders': Brainwashing, Culture, Clinical Knowledge and the Cold War Human Sciences, c. 1950–1990'; was fellow and training analyst of the British Psychoanalytical Society and author of numerous articles and several books on modern cultural history, psychoanalysis, and history of the human sciences.
=== Laboratory automation development === Markin's interest in laboratory automation, blending clinical processes with information technology, began during his graduate studies, which focused on graph theory. By 1989, he developed a prototype system that would later allow "plug-and-play" integration of automation systems and clinical analyzers for managing and testing of patient specimens. His approach was to build an automated transport system which would allow various testing processes using commercial, off-the-shelf testing and collection systems. He didn't design the instruments, but sought an automated system to manage the testing processes, leading to increased efficiency, improved reporting and lower laboratory costs. He founded LAB-InterLink in 1993, and commercialized a system to manage clinical specimens using an automated transportation system and specimen processing devices (i.e. decapping devices, recapping devices, instrument or analyzer interfaces, etc.) for laboratory testing and processing. For example, the specimen would be separated using a centrifuge; the specimen container would be uncapped; the specimen would be tested as ordered by the physician; the container would be recapped; and the specimen would be stored in the event further testing is needed. Test results were provided to the physician or provider as part of the software management system. LAB-InterLink sold automation systems in North America and internationally, and offices were set up in the United States, Canada and Israel. In 2004, the U.S.
== External links == CID 16132316 from PubChem – β-endorphin CID 3081525 from PubChem – β-endorphin (1-9) CID 133304 from PubChem – β-endorphin (2-9) β-endorphin at the U.S. National Library of Medicine Medical Subject Headings (MeSH)
Sources: en.wikipedia.org
The stability of nuclei quickly decreases with the increase in atomic number after curium, element 96, whose half-life is over ten thousand times longer than that of any subsequent element. All isotopes with an atomic number above 101 undergo radioactive decay with half-lives of less than 30 hours: this is because of the ever-increasing Coulomb repulsion of protons, so that the strong nuclear force cannot hold the nucleus together against spontaneous fission for long. Calculations suggest that in the absence of other stabilising factors, elements with more than 103 protons should not exist. Researchers in the 1960s suggested that the closed nuclear shells around 114 protons and 184 neutrons should counteract this instability, and create an "island of stability" containing nuclides with half-lives reaching thousands or millions of years. The existence of the island is still unproven, but the existence of the superheavy elements (including nihonium) confirms that the stabilising effect is real, and in general the known superheavy nuclides become longer-lived as they approach the predicted location of the island. All nihonium isotopes are unstable and radioactive; the heavier nihonium isotopes are more stable than the lighter ones, as they are closer to the centre of the island. The most stable known nihonium isotope, 286Nh, is also the heaviest; it has a half-life of 8 seconds. The isotope 285Nh, as well as the unconfirmed 287Nh and 290Nh, have also been reported to have half-lives of over a second.
=== Ireland === In 2019, the chain announced plans to open a restaurant in Dublin, Ireland, with 40 total sites in Ireland planned from 2020. As of early 2026, there are two locations in Ireland, both of them in Dublin.
=== Further reading === Resnick D, Niwayama G (January 1983). "Entheses and enthesopathy. Anatomical, pathological, and radiological correlation". Radiology. 146 (1): 1–9. doi:10.1148/radiology.146.1.6849029. PMID 6849029.
Sources: en.wikipedia.org
Dihexa is a synthetic peptide derived from angiotensin IV and studied for effects on synaptic plasticity. It is often described as a hepatocyte growth factor mimetic. It is not an approved medication.
It is based on angiotensin IV, a naturally occurring peptide fragment, but dihexa itself is chemically modified and synthetic. The modifications aim to improve stability and activity compared with the parent fragment.
Laboratory studies have used cell-based assays and rodent models. These examine receptor signaling, dendritic spine changes, and behavioral tasks. Published human clinical trial data are lacking.
Dihexa has been reported to activate hepatocyte growth factor/c-Met signaling in cell studies. This pathway is linked to synapse formation and neuronal remodeling. The exact molecular interactions are not fully understood.